focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Contract Signed with ScandiNova

22 Jul 2014 07:00

RNS Number : 9237M
Advanced Oncotherapy PLC
22 July 2014
 



22 July2014

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

 

Contract Signed with ScandiNova Systems AB

 

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of particle therapy using protons to treat cancer, announces that it has entered into a collaboration with industry leader ScandiNova Systems AB ("ScandiNova"). ScandiNova will develop the high energy systems that will power the unit of the proprietary LIGHT system which will create the proton beam.

 

ScandiNova was founded in 2001 to commercialise technical expertise in pulsed power applications including Radiotherapy, Radar, industrial X-ray and scientific accelerator systems. The company is located in Uppsala, Sweden and has established a global network of collaborations with highly skilled and experienced partners covering industry, academia and research organisations such as CERN in Europe, Lawrence Livermore and Brookhaven National Laboratories in the US.

ScandiNova specialises in the development of solid state controlled power systems which require about one third of the space and are 30% more efficient than those used in standard, older technology - synchrotrons.

Mikael Lindholm, Founder, Senior VP Sales & Marketing ScandiNova, commented: "We have been working with ADAM since 2007 and from the very start have seen the potential in the LIGHT technology which should deliver a superior proton therapy technology. Our Solid State Pulse Power products are widely used and are now installed in 28 different countries in Europe, Asia, Australia, and North and South America. For us, it is a privilege to be working with an organisation which could become the number one supplier of the next generation of proton therapy. "

 

Sanjeev Pandya, CEO of Avdanced Oncotherapy, added: "In our due diligence prior to the acquisition of the LIGHT technology, it became clear that there were already many world class partners involved in the development of the LIGHT programme. ScandiNova is one such partner and I am really pleased to be able to make this announcement. Advanced Oncotherapy is going to continue this relationship and ScandiNova will become a key partner and supplier in helping us develop our complete LIGHT system."

 

For further information contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya (CEO)

Tel: +44 20 3617 8739

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

 

Beaufort Securities (Joint Broker)

 

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

 

 

Walbrook PR (Financial PR & IR)

avo@walbrookpr.com

Anna Dunphy / Mike Wort

 

Tel: +44 20 7933 8780

 

About Advanced Oncotherapy Plc

 

Mission:

To facilitate the wider use of particle therapy with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.

 

Key corporate messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

AVO is a provider of proton radiotherapy that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

 

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

For more information, please visit http://www.avoplc.com

 

About ScandiNova

 

ScandiNova Systems AB is a company based in Uppsala, Sweden. The company has an office in USA and representatives in 8 other countries. The company is growing continuously, since many customers in various applications are leaving the old traditional technology.

 

ScandiNova provides advanced high power Pulse Generators and fully integrated RF units, providing RF power up to 100MW and voltage pulses up to 500kV. The ScandiNova products are based on a unique patented Solid State parallel switching technology, which provides very high reliability and exceptional pulse quality and precision. Additionally, the power consumption is about 30% less than the traditional technology, which in high power applications is an important environmental requirement.

 

ScandiNova is supported by its main strong owners SEB Ventures (part of the biggest Swedish Bank SEB) and Industrifonden (the biggest government initiated fund).

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTVFLFLZDFFBBQ
Date   Source Headline
11th Oct 201611:37 amRNSHolding(s) in Company
11th Oct 201610:54 amRNSHolding(s) in Company
10th Oct 201611:44 amRNSDirectorate Change
30th Sep 20167:45 amRNSSubscription and Proposed Open Offer
30th Sep 20167:00 amRNSHalf-year Report
6th Sep 20167:00 amRNSAppointment of Director of Medical Physics
4th Aug 20165:05 pmRNSHolding(s) in Company
4th Aug 20168:13 amRNSHolding(s) in Company
27th Jul 20167:00 amRNSExercise of warrants
19th Jul 201611:27 amRNSHolding(s) in Company
19th Jul 201611:24 amRNSHolding(s) in Company
12th Jul 20167:00 amRNSDirector/PDMR Shareholding
11th Jul 201610:06 amRNSDirector/PDMR Shareholding
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
7th Jul 20166:01 pmRNSDirector/PDMR Shareholding
30th Jun 20164:19 pmRNSResult of AGM and share consolidation
22nd Jun 20167:00 amRNSAGM Presentation
7th Jun 20167:00 amRNSExercise of options and issue of shares
31st May 20167:00 amRNSFinal Results
26th May 20167:00 amRNS£24m financing secured for Harley Street
12th May 20164:02 pmRNSHolding(s) in Company
3rd May 20169:01 amRNSUpdate on Harley Street
18th Apr 20167:00 amRNSExercise of warrants and issue of shares
29th Mar 20167:00 amRNSUpdate on development milestones
1st Mar 20167:00 amRNSSenior Management Appointments
22nd Feb 20165:02 pmRNSHolding(s) in Company
8th Feb 20167:01 amRNSDirectorate Change
8th Feb 20167:00 amRNSThales industrialisation agreement
4th Feb 201612:35 pmRNSNomad change of name
21st Dec 20157:00 amRNSDirectors' Dealing
18th Dec 20152:42 pmRNSDirector Dealing
17th Dec 20159:40 amRNSDirector Dealing
24th Nov 20158:06 amRNSAppointment of Executive Chairman at ADAM
18th Nov 20157:00 amRNSDisposal of ORL
16th Nov 20157:00 amRNSSuccessful high power testing of CCL modules
21st Oct 20157:00 amRNSSecond commercial sale of proton therapy system
12th Oct 20157:00 amRNSOperator agreement with CircleHealth for Harley St
12th Oct 20157:00 amRNSStatement regarding new cancer centre
22nd Sep 20157:00 amRNSHalf Yearly Report
21st Sep 20153:31 pmRNSNotice of Results
21st Sep 20157:00 amRNSFirst milestone payment for China LIGHT system
3rd Sep 20159:34 amRNSChange of Registered Office & Trading address
24th Aug 20157:00 amRNSCCL modules ready for high-power testing
20th Aug 20157:00 amRNSSinophi agreement with Jilin University
10th Aug 201511:16 amRNSHolding(s) in Company
31st Jul 20157:00 amRNSExercise of warrants and options & issue of shares
29th Jul 20157:00 amRNSExercise of warrants and issue of shares
28th Jul 20157:00 amRNSDelivery of additional CCL unit & Harley St update
20th Jul 20153:10 pmRNSReplacement: Director Dealing and Award of Options
20th Jul 20157:00 amRNSDirector Dealing and Award of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.